17.2.2017 – Our new article on insulins NPH, glargine, and detemir, and risk of severe hypoglycemia has been published in Annals of Medicine. The comparative safety of modern basal insulins regarding hypoglycemia among the working-age population has been unclear. Large reductions in the incidence of severe hypoglycemia were seen among real-life patients who started insulin detemir, as […]
15.2.2017 – EPID Research is proud to sponsor ISPE’s 2017 Mid-Year Meeting in London. ISPE, the International Society for Pharmacoepidemiology, is a non-profit international professional membership organisation dedicated to advancing the health of the public. We look forward to meeting you at the event! We will have a tabletop exhibit there for you to find us easily. Also, you’re welcome […]
8.2.2017 – Our recently published article on lower death risk for vascular dementia than for Alzheimer’s disease with postmenopausal hormone therapy users in the Journal of Endocrinology & Metabolism has been cited in the Duodecim publication (in Finnish) – for subscribers: Duodecim article
1.2.2017 – Our business is growing and new talented people have joined us. Therefore, our Swedish branch has moved to a new office in Little Bommen, Gothenburg. The new address is: EPID Research Sweden branch Little Bommen 6, 7th Floor SE-411 04 Gothenburg, Sweden For more information, please contact firstname.lastname@example.org.
16.01.2017 – StatFinn and EPID Research have decided to merge their operations in order to offer a full range of services to their clients in clinical data analytics and Real-World Evidence from Phase I to Phase IV and beyond. The combined company employs over 70 experts with presence in five countries: Estonia, Finland, Poland, Sweden […]